BridgeBio Pharma has announced encouraging results from a pivotal clinical study evaluating its investigational drug, BBP-418, for a subtype of limb-girdle muscular dystrophy (LGMD type 2I/R9)—a progressive condition caused by mutations that weaken muscles over time and, currently, has no available treatments. The late-stage trial enrolled patients with this rare genetic disorder and tracked outcomes over the course of a year.
After three months of treatment, participants who received BBP-418 experienced a substantial rise in glycosylated alpha-dystroglycan, a biomarker essential for stabilizing muscle cells, with levels rising by nearly 1.8 times compared to placebo. This improvement persisted through 12 months, accompanied by an 82% reduction in serum creatine kinase—an indicator of muscle damage—and measurable enhancement in the speed of walking and forced lung capacity relative to untreated peers. The trial’s statistical results were described by independent analysts as far exceeding previous expectations for this experimental approach.
No new or unusual safety issues emerged during the trial, and adverse events were consistent with earlier studies. These positive findings position BridgeBio to seek FDA approval for BBP-418, with plans to file an application in the first half of 2026. The company’s breakthrough could mark a turning point for thousands living with LGMD2I/R9, offering a pathway to the first disease-modifying therapy where none exist today.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!